Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Glioma 2Central Nervous System Neoplasms 2Brain Neoplasms 2Triple Negative Breast Neoplasms 1Sarcoma 1Prostatic Neoplasms 1Myasthenia Gravis 1Multiple Myeloma 1Hematologic Neoplasms 1Gliosarcoma 1Glioblastoma 1Breast Neoplasms 1Breast Diseases 1Astrocytoma 1Arthritis, Rheumatoid 1

Interventions

Dexamethasone 363Bortezomib 232Lenalidomide 202Cyclophosphamide 174Melphalan 154Calcium Dobesilate 107Peripheral Blood Stem Cell Transplantation 92fludarabine phosphate 84Thalidomide 81Filgrastim 71carfilzomib 68pomalidomide 66Granulocyte Colony-Stimulating Factor 60Mycophenolic Acid 59Busulfan 57daratumumab 55Whole-Body Irradiation 54Tacrolimus 51ixazomib 50Prednisone 50Cyclosporine 49fludarabine 46Antilymphocyte Serum 35Etoposide 30dexamethasone acetate 29Methotrexate 29plerixafor 27Radiotherapy 26Doxorubicin 26dexamethasone 21-phosphate 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Multiple Myeloma × Leflunomide × Clear all
NCT02509052 2023-10-10

Leflunomide in Treating Patients With Relapsed or Refractory Multiple Myeloma

City of Hope Medical Center

Phase 1/2 Completed
12 enrolled 21 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡